While diagnostic cytopathology is a standard of care method to test for dysplasia and cancer, its use is often limited by inadequate specimen cellularity. 
 

Founded in 2018, Adenocyte™ is focused on development of its patented discovery that the brief, extracorporeal application of a specially designed, FDA cleared, low intensity, non-focused ultrasound (“LINFU®) beam, can significantly increase the natural rate of epithelial cell exfoliation into a surrounding body fluid – enhancing cytological specimens used to screen for dysplasia and cancer.

 

The first clinical application of LINFU® is to enrich the pancreatic juice cytopathology specimen used to screen high risk asymptomatic patients for the presence of ductal dysplasia (PanIn-2 and PanIn-3) and early carcinoma (PDAC).